

Supplementary Online Content

Stockwell MS, Broder K, LaRussa P, et al. Risk of fever from pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine [published online January 6, 2014]. *JAMA Pediatr*. doi:10.1001/jamapediatrics.2013.4469.

eTable 1: Most Frequent Patterns of Vaccination on Enrollment Day

eTable 2: Bivariate Analysis of Association Between Demographic and Health Characteristics of Study Population and Fever on Days 0 to 1 After Vaccination

eTable 3: Fever Rates After Simultaneous Vaccination With Trivalent Inactivated Influenza (TIV) and 13-Valent Pneumococcal Conjugate (PCV13) vs TIV or PCV13 Administration Without the Other Vaccine Using the Pearson χ^2 Test, Relative Ratios, and Multivariable Log-Binomial Regression (Full Model)

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1: Most Frequent Patterns of Vaccination on Enrollment Day

Vaccines Administered	Study Group			
	Total (n=530)	TIV (n=208)	PCV13/TIV (n=212)	PCV13 (n=110)
TIV (no other vaccine)	24.5%	62.5%	0%	0%
TIV-PCV13-(DTaP-Hib-IPV)*-Hep B	19.6%	0%	49.1%	0%
PCV13-MMR-Varicella-Hep A	11.3%	0%	0%	54.5%
TIV-PCV13-MMR-Varicella	5.7%	0%	14.2%	0%
TIV-(DTaP-Hib-IPV)*-Hep A	5.1%	13.0%	0%	0%
TIV-PCV13-(DTaP-Hib-IPV)*-Hep B-Rotavirus	4.2%	0%	10.4%	0%
TIV-(DTaP-Hib-IPV)*	3.8%	9.6%	0%	0%
PCV13-(DTaP-Hib-IPV)*-Hep B	3.0%	0%	0%	14.5%
TIV-PCV13-(DTaP-Hib-IPV)*	3.0%	0%	7.5%	0%
TIV-PCV13-MMR-Varicella-Hep A	2.6%	0%	6.6%	0%
PCV13-(DTaP-Hib-IPV)*	2.5%	0%	0%	11.8%
PCV13-MMR-Varicella	1.7%	0%	0%	8.2%
TIV-Hep A	1.5%	3.8%	0%	0%

Notes:

- (1) Trivalent inactivated influenza vaccine (TIV); 13-valent pneumococcal conjugate vaccine (PCV13); Diphtheria/tetanus/acellular pertussis (DTaP), Inactivated polio virus (IPV); Haemophilus influenzae B (Hib); Hepatitis B (Hep B); Hepatitis A (Hep A); Measles/Mumps/Rubella (MMR); *DTaP-Hib-IPV: majority (96%) administered as Pentacel®
- (2) Rest of individual combinations <1%
- (3) One child received PCV13 and no other vaccine, and one child received PCV13 and TIV and no other vaccine

eTable 2: Bivariate Analysis of Association Between Demographic and Health Characteristics of Study Population and Fever on Days 0 to 1 After Vaccination

Enrollees: N = 413	Temperature $\geq 38^{\circ}\text{C}$ days 0-1 (N=84)	P value	Temperature $\geq 39^{\circ}\text{C}$ days 0-1 (N=27)	P value
Child Age 6-11 months (n=230) 12-23 months (n=183)	58 (25.2) 26 (14.2)	.01	16 (7.0) 11 (6.0)	.70
Child Gender Female (n=214) Male (n=199)	39 (18.2) 45 (22.6)	.27	13 (6.1) 14 (7.0)	.69
Child Race/Ethnicity Latino (n= 360) Black non-Latino (n=45) White non-Latino (n=5) Other non-Latino (n=3)	72 (20.0) 11 (24.4) 0 (0.0) 1 (33.3)	.60	24 (6.7) 3 (6.7) 0 (0.0) 0 (0.0)	.90
Month of Enrollment November (n= 25) December (n=56) January (n=83) February (n=119) March (n= 110) April (n=20)	8 (32.0) 12 (21.4) 12 (14.5) 26 (21.8) 23 (20.9) 3 (15.0)	.49	3 (12.0) 4 (7.1) 4 (4.8) 8 (6.7) 8 (7.3) 0 (0.0)	.68
Child High Risk for Complications from Influenza ¹¹ Yes (n=25) No (n=388)	4 (16.0) 80 (20.6)	.58	2 (8.0) 25 (6.4)	.76
Family Member with Previous Vaccine Reaction Yes (n= 13) No (n = 398) Unknown (n= 2)	3 (23.1) 81 (20.4) 0 (0.0)	.75	1 (7.7) 26 (6.5) 0 (0.0)	.92
Previous Influenza Vaccine No (N= 151) Yes (n=262)	55 (36.4) 29 (11.1)	<.0001	14 (9.3) 13 (5.0)	.09

eTable 3: Fever Rates After Simultaneous Vaccination With Trivalent Inactivated Influenza (TIV) and 13-Valent Pneumococcal Conjugate (PCV13) vs TIV or PCV13 Administration Without the Other Vaccine Using the Pearson χ^2 Test, Relative Ratios, and Multivariable Log-Binomial Regression (Full Model)

	Temperature $\geq 38^\circ\text{C}$ days 0-1			Temperature $\geq 39^\circ\text{C}$ days 0-1		
	Frequency	RR (95% CI)	Adjusted RR (95% CI)	Frequency	RR (95% CI)	Adjusted RR (95% CI)
Vaccine type						
TIV/PCV13 (n = 170)	37.6%	Reference	Reference	11.2%	Reference	Reference
TIV (n = 159)	7.5%	0.20 (0.11, 0.36)	0.37 (0.18,0.77)	2.5%	0.23 (0.08, 0.65)	0.26 (0.07,0.92)
PCV13 (n=84)	9.5%	0.25 (0.13, 0.50)	0.38 (0.18,0.80)	4.8%	0.43 (0.15, 1.21)	0.40 (0.12,1.31)
Age						
6-11 months (n=230)	25.2%	1.77 (1.17-2.70)	0.53 (0.21, 1.36)	7.0%	1.16 (0.55, 2.43)	0.68 (0.12,3.72)
12-23 months (n=183)	14.2%	Reference	Reference	6.0%	Reference	Reference
Hepatitis A						
Yes (n=104)	9.6%	0.40 (0.22, 0.75)	0.70 (0.33,1.49)	5.8%	0.85 (0.35, 2.05)	1.28 (0.39, 4.19)
No (n=309)	23.9%	Reference	Reference	6.8%	Reference	Reference
Hepatitis B						
Yes (n=134)	38.8%	3.38 (2.29,4.99)	1.60 (0.53, 4.83)	10.4%	2.24 (1.08, 4.64)	1.91 (0.26, 14.26)
No (n=279)	11.5%	Reference	Reference	4.7%	Reference	Reference
Pentacel						
Yes (n=187)	32.6%	3.21 (2.07, 4.97)	1.62 (0.96, 2.74)	9.6%	2.42 (1.11, 5.25)	1.65 (0.65, 4.23)
No (n=226)	10.2%	Reference	Reference	4.0%	Reference	Reference
Previous Influenza Vaccine						
No (n=151)	36.4%	3.29 (2.20, 4.92)	1.29 (0.63, 2.65)	9.3%	1.86 (0.90, 3.87)	0.59 (0.16, 2.22)
Yes (n=262)	11.1%	Reference	Reference	5.0%	Reference	Reference

RR: Relative Risk, CI: Confidence Intervals